A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

Cancer

Volumn 118, Issue 22, 2012, Pages 5601-5607

  Nabors, L Burt ^a   Mikkelsen, Thomas ^b   Hegi, Monika E ^c   Ye, Xiaubu ^d   Batchelor, Tracy ^e   Lesser, Glenn ^f   Peereboom, David ^g   Rosenfeld, Myrna R ^h   Olsen, Jeff ⁱ   Brem, Steve ^h   Fisher, Joy D ^d,j   Grossman, Stuart A ^k  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f WAKE FOREST BAPTIST HEALTH   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j University of Alabama at Birmingham   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

angiogenesis; cilengitide; clinical trial; glioblastoma; integrin

Indexed keywords

AMD 121974; CILENGITIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME ACTIVITY; FATIGUE; FEMALE; GLIOBLASTOMA; HEARTBURN; HUMAN; HUMAN TISSUE; HYPONATREMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SURVIVAL RATE; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; INTEGRINS; MALE; MIDDLE AGED; SNAKE VENOMS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84868193304     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27585     Document Type: Article

References (15)

1. Goodman SL, Holzemann G, Sulyok GA, Kessler H,. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J Med Chem. 2002; 45: 1045-1051.
2. Germer M, Kanse SM, Kirkegaard T, et al. Kinetic analysis of integrin-dependent cell adhesion on vitronectin-the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem. 1998; 253: 669-674.
3. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS,. Alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis. 2003; 6: 105-119.
4. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY,. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol. 2000; 46: 135-144.
5. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha5(v) integrin antagonist. Neurosurgery. 2001; 48: 151-157.
6. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE,. Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery. 2006; 59: 1304-1312; discussion 1312.
7. Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer. 2009; 124: 2719-2727.
8. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007; 25: 1651-1657.
9. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008; 26: 5610-5617.
10. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010; 28: 2712-2718.
11. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn. 2008; 10: 332-337.
12. Kaplan E, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
13. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
14. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.
15. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011; 29: 142-148.